Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALDX logo ALDX
Upturn stock rating
ALDX logo

Aldeyra The (ALDX)

Upturn stock rating
$5.66
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/15/2025: ALDX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $9.67

1 Year Target Price $9.67

Analysts Price Target For last 52 week
$9.67 Target price
52w Low $1.14
Current$5.66
52w High $7.2

Analysis of Past Performance

Type Stock
Historic Profit -27.33%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulation Last Close 10/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 320.64M USD
Price to earnings Ratio -
1Y Target Price 9.67
Price to earnings Ratio -
1Y Target Price 9.67
Volume (30-day avg) 7
Beta 0.82
52 Weeks Range 1.14 - 7.20
Updated Date 10/15/2025
52 Weeks Range 1.14 - 7.20
Updated Date 10/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.85

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -31.58%
Return on Equity (TTM) -65.91%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 253078475
Price to Sales(TTM) -
Enterprise Value 253078475
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.5
Shares Outstanding 60045530
Shares Floating 48631475
Shares Outstanding 60045530
Shares Floating 48631475
Percent Insiders 3.1
Percent Institutions 58.17

ai summary icon Upturn AI SWOT

Aldeyra The

stock logo

Company Overview

overview logo History and Background

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies to improve the lives of patients with immune-mediated diseases. Founded in 2004, Aldeyra initially focused on aldehyde dehydrogenase (ALDH) enzymes. Over time, Aldeyra has expanded its focus to broader immune-mediated diseases.

business area logo Core Business Areas

  • Ophthalmology: Aldeyra focuses on developing therapies for ocular diseases, including allergic conjunctivitis and dry eye disease.
  • Systemic Immune-Mediated Diseases: Aldeyra explores the development of therapies to treat systemic immune-mediated diseases.

leadership logo Leadership and Structure

The leadership team consists of Dr. Todd C. Brady (CEO), and Richard Edelson (President). The company operates with a functional organizational structure centered around research, clinical development, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • Reproxalap: Reproxalap is a small-molecule RASP (reactive aldehyde species) inhibitor in late-stage development for allergic conjunctivitis and dry eye disease. Market share data is not yet available as the product is not yet approved but peak sales expectations are in the hundreds of millions. Competitors for allergic conjunctivitis include Alcon (ALC) and Bausch + Lomb (BLCO). Competitors for dry eye include Novartis (NVS) and AbbVie (ABBV).
  • ADX-2191: ADX-2191 is an intravitreal formulation of methotrexate in development for proliferative vitreoretinopathy (PVR). Market data is not available since it is currently in the development pipeline. Competitors for PVR include Alcon and other companies focused on vitreoretinal surgery solutions.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, particularly the segments focused on ophthalmology and immune-mediated diseases, is characterized by high competition and rigorous regulatory requirements. Companies invest heavily in research and development to bring innovative therapies to market.

Positioning

Aldeyra positions itself as an innovator in the ophthalmology and immune-mediated disease space, with a focus on developing therapies with novel mechanisms of action. Its RASP inhibitor technology gives it a competitive edge. It has a competitive niche in dry eye disease space, but it also faces competition from large companies with already-established drugs for dry eye.

Total Addressable Market (TAM)

The TAM for dry eye disease and allergic conjunctivitis is estimated to be several billion dollars globally. Aldeyra aims to capture a significant share of these markets with Reproxalap. The TAM for PVR is smaller, but ADX-2191 has the potential to address an unmet medical need.

Upturn SWOT Analysis

Strengths

  • Novel RASP inhibitor technology
  • Late-stage product candidates
  • Experienced management team
  • Focus on unmet medical needs

Weaknesses

  • Reliance on successful clinical trial outcomes
  • Dependence on regulatory approvals
  • Limited commercial infrastructure
  • History of losses

Opportunities

  • Potential to expand product pipeline through acquisitions or licensing
  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Positive clinical data for Reproxalap

Threats

  • Competition from established pharmaceutical companies
  • Unfavorable regulatory decisions
  • Clinical trial failures
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • NVS
  • ABBV
  • ALC
  • BLCO

Competitive Landscape

Aldeyra is at a disadvantage currently because of its lack of commercialized products compared to its competitors, although they have a promising novel therapy, and niche areas. In dry eye and allergic conjuctivitis, Novartis, AbbVie, Alcon and Bausch + Lomb are established players with proven products and established brand recognition. However, Aldeyra's RASP inhibitor offers a different mechanism of action that could prove advantageous. The main advantage will be regulatory approval, successful commercialization and revenue.

Growth Trajectory and Initiatives

Historical Growth: Aldeyra's historical growth is measured by advancement of clinical programs and successful fundraising, not by traditional revenue growth.

Future Projections: Future growth is contingent on successful Reproxalap approval and commercialization, and further development of pipeline programs. Analyst estimates for future revenue vary greatly depending on approval timelines.

Recent Initiatives: Recent initiatives include filing of Reproxalap NDA and advancement of ADX-2191 into clinical trials.

Summary

Aldeyra Therapeutics is a clinical-stage company focused on ophthalmology and immune-mediated diseases, with promising novel RASP inhibitor technology. The company needs approval and successful commercialization of Reproxalap. It needs to expand beyond their first FDA approval. Clinical trial outcomes and regulatory decisions are key to the company's success, and its commercial infrastructure will need to be built out or partnered with a larger company. It has a history of losses but good recent revenue.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Industry Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be complete or accurate. Investment decisions should be made after consulting with a qualified financial advisor.

Upturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Aldeyra The

Exchange NASDAQ
Headquaters Lexington, MA, United States
IPO Launch date 2014-05-02
CEO, President & Director Dr. Todd C. Brady M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.